Kitty C. M. Verhoeckx

Kitty C. M. Verhoeckx

Auto-generated profile, based on publicly available information

Kitty C. M. Verhoeckx

Department of Dermatology/Allergology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
SDStephanie Dramburg
Stephanie Dramburg
Christiane HilgerChristiane Hilger
Christiane Hilger
ASAlexandra F Figueira Santos
Alexandra F Figueira Santos
LVLeticia de las Vecillas
Leticia de las Vecillas
RARob C. Aalberse
Rob C. Aalberse
KHKarin Hoffmann-Sommergruber
Karin Hoffmann-Sommergruber
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE‐mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE‐mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well‐defined, highly pure molecules for component‐resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state‐of‐the‐art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.

7 January 2021 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
Joana CostaJoana Costa
Joana Costa
Caterina VillaCaterina Villa
Caterina Villa
KVKitty Verhoeckx
Kitty Verhoeckx
TVTanja Cirkovic Velickovic
Tanja Cirkovic Velickovic
Denise SchramaDenise Schrama
Denise Schrama
THThomas Holzhauser
Thomas Holzhauser

2 September 2020 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
Joana CostaJoana Costa
Joana Costa
SBSimona Lucia Bavaro
Simona Lucia Bavaro
SBSara Benedé
Sara Benedé
Araceli Díaz-PeralesAraceli Díaz-Perales
Araceli Díaz-Perales
CBCristina Bueno-Diaz
Cristina Bueno-Diaz
THThomas Holzhauser
Thomas Holzhauser

20 July 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
BHBregje C. Holleman
Bregje C. Holleman
HOHarmieke van Os‐Medendorp
Harmieke van Os‐Medendorp
HBHuub van Den Bergh
Huub van Den Bergh
LDLiselotte M. van Dijk
Liselotte M. van Dijk
YLYvette F.M. Linders
Yvette F.M. Linders
LLLeo R. Lentz
Leo R. Lentz
Background: Understanding consumers’ interpretation of allergy information is crucial for effective food safety policies. We evaluated consumer understanding of allergy information on foods in controlled, experimental studies.Method: Using 18 packaged foods, we evaluated consumer understanding of information about allergens in two experiments: First, a comparison of foods with no stated allergen versus allergen as a stated ingredient versus a precautionary allergen label (PAL); second, a comparison of three common variants of PAL. In each experiment, consumers with and without self‐reported food allergy were asked to estimate the risk of allergic reaction and to rate the comprehensibility of the allergen information. In the second experiment, consumers were also asked which form of PAL they preferred.Results: Risk of reaction was assessed as high and low for foods with the allergen stated as ingredient, or without any mention of allergen. However, risk assessment for PAL varied and was judged as higher by non‐allergic than allergic participants (82% vs. 58%, p < .001). Understanding of risk associated with PAL also varied by health literacy (p < .001). Both allergic and non‐allergic consumers judged all forms of allergy information to be unclear, especially products with no allergy information for non‐allergic consumers. Products with a ‘Produced in a Factory’ PAL were perceived as less risky than ‘May contain’ or ‘Traces of’ PALs (p < .001), less than 40% of participants judged PAL information to be comprehensible, and participants preferred ‘May contain’ over the other PALs.Conclusion: Both allergic and non‐allergic consumers find allergen information difficult to interpret on packaged foods and misunderstand PAL, incorrectly distinguishing different risk levels for different PAL wording. Clearer allergy information guidelines are called for, and the use of only one PAL wording is recommended.

13 January 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
WBW. Marty Blom
W. Marty Blom
LDLiselotte M. van Dijk
Liselotte M. van Dijk
AMAnouska Michelsen‐Huisman
Anouska Michelsen‐Huisman
GHGeert F. Houben
Geert F. Houben
AKAndré C. Knulst
André C. Knulst
LLLeo R. Lentz
Leo R. Lentz
Background: Allergen information on product labels is crucial in food allergy management, though inadequacy in current labelling practices is one of the major causes for accidental reactions upon consuming prepacked food products.Objective: This study analyses current status of communicating allergen information on food labels and provides practical recommendations for improving the label format based on communication theory.Methods: Product labels (N 288) of seven food categories from private label products and brands were obtained at three retailers in the Netherlands. Information regarding the 14 EU‐regulated allergens was evaluated by the frequency of emphasizing allergens in the ingredient list, use of precautionary allergen labelling (PAL), icons and an allergen information section. Effectiveness of communication was assessed evaluating readability and findability of information on allergens using principles of Gestalt and Cognitive Load theories.Results: As requested by EU regulation 1169/2011, emphasizing allergens in the ingredient list was almost 100%, all other presentations of information on allergens on labels was highly diverse. A separate allergen information section was present on most private label products. This section could, but not necessarily did, repeat allergens from the ingredient list and/or give a PAL. Brands often provided a PAL at the end of the ingredient list. Part of the products displayed an icon at different locations of the label. Label background, a lack of cohesion and variation in location of topics hamper the identification of relevant information on allergens by (allergic) consumers. Recommendations include a standardized order for mandatory and voluntary topics on the label and a separate allergen information section.Conclusion and clinical relevance: Overall, consumers encounter a wide and inconsistent range in ways of presentation of allergen information on labels. Standardization according to basic design principles can improve usability and support safe food purchases for allergic consumers.

18 May 2020 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
KVKitty Verhoeckx
Kitty Verhoeckx
KBKatrine Lindholm Bøgh
Katrine Lindholm Bøgh
ACAnne Constable
Anne Constable
MEMichelle M. Epstein
Michelle M. Epstein
KHKarin Hoffmann-Sommergruber
Karin Hoffmann-Sommergruber
RCRené Crevel
René Crevel
The growing world population and increased pressure on agricultural resources are driving a shortage of dietary protein sources. As a result, industry is developing more sustainable novel food protein sources such as insects, algae and duckweed and using new processing techniques. Consumer exposure to these novel or processed proteins, could cause new food allergies, exacerbating a public health issue which is already directly affecting an estimated 20 million Europeans. Introduction of novel foods should not add to the burden of food allergy and this calls for a reliable, harmonised, evidence-based and validated allergenicity risk assessment strategy. The COST (Cooperation in Science and Technology) Action ImpARAS (Improved Allergenicity Risk Assessment Strategy), a four-year networking project, identified gaps in current allergy risk assessment, and proposed new ideas and plans for improving it. Here, we report on the lessons learned from the ImpARAS network and suggestions for future research. The safe introduction of novel and more sustainable food protein sources, while protecting humans from food allergy, calls for a multidisciplinary approach based on an improved understanding of what determines the relative allergenic potency of proteins, novel testing and assessment methodologies, harmonized decision-making criteria, and a clear ranking approach to express the allergenicity of novel product relative to that of existing known allergenic proteins: (from ‘non’/to weakly and to strongly allergenic proteins).